Full Press Release Details
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos...
BMY Positive Sentiment
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
Key Takeaway: Bristol Myers Squibb presented 56-week Phase 3 data for Camzyos (mavacamten) in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The findings were shared at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions. This data highlights the potential effectiveness of Camzyos in this patient population.
Market Sentiment Analysis
POSITIVE FACTORS
- 56-week Phase 3 data presented
- Focus on pediatric patients
- Potential benefits of Camzyos in oHCM
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+19%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
Mezigdomide
NDA/BLA · Relapsed or Refractory Multiple Myeloma
Frequently Asked Questions
What is Camzyos used for?
Camzyos (mavacamten) is used to treat symptomatic obstructive hypertrophic cardiomyopathy.
What were the results of the Phase 3 study?
The study presented 56-week data showing potential benefits for pediatric patients.
Where was the data presented?
The data was presented at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions.
Who conducted the Phase 3 study?
The study was conducted by Bristol Myers Squibb.